[PDF][PDF] Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms
R Perry, AM Small, WH Green - Am J Psychiatry, 1984 - Citeseer
R Perry, AM Small, WH Green
Am J Psychiatry, 1984•CiteseerIn this double-blind, placebo-controlled study the administration of haloperidol resulted in
significant decreases in behavioral symptoms and in general clinical improvement in 40
autistic children ages 2.33 to 6.92 years. Haloperidol also produced greater facilitation and
retention of discrimination learning in the laboratory. No adverse effects were observed at
therapeutic doses, which ranged from 0.5 to 3.0 mg/day or 0.01 9 to 0.2 17 mg/kg per day.
significant decreases in behavioral symptoms and in general clinical improvement in 40
autistic children ages 2.33 to 6.92 years. Haloperidol also produced greater facilitation and
retention of discrimination learning in the laboratory. No adverse effects were observed at
therapeutic doses, which ranged from 0.5 to 3.0 mg/day or 0.01 9 to 0.2 17 mg/kg per day.
In this double-blind, placebo-controlled study the administration of haloperidol resulted in significant decreases in behavioral symptoms and in general clinical improvement in 40 autistic children ages 2.33 to 6.92 years. Haloperidol also produced greater facilitation and retention of discrimination learning in the laboratory. No adverse effects were observed at therapeutic doses, which ranged from 0.5 to 3.0 mg/day or 0.01 9 to 0.2 17 mg/kg per day.
Citeseer